Gandara DR, Von Pawel J, Sullivan RN, Helland A, Han JY, Aix SP, et al. Impact of atezolizumab (atezo) treatment beyond disease progression (TBP) in advanced NSCLC: Results from the randomized Phase III OAK study. J Clin Oncol 35, 2017 (suppl; abstr 9001) 24. Garassino MC, Martelli O, Broggini M, Farina G, Veronese S, Rulli E, et al. Erlotinib versus docetaxel as second -line treatment of patients with advanced non -small -cell lung cancer and wild-type EGFR tumours (TAILOR): a randomised controlled trial. Lancet Oncol.